ATP1A1 and cancer: For example, a combination of conventional anti-cancer drugs effectively prevented relapses in a TNBC xenograft model [48], and an MAP kinase inhibitor and CGs synergistically induced cell death by targeting ATP1A1 in a mouse melanoma model [49].